Published in final edited form as:

EuroIntervention. ; 12(18): e2163–e2165. doi:10.4244/EIJV12I18A355.

Renal denervation for treatment of hypertension – will 2017 be the year of enlightenment?

Felix Mahfoud, MD^{1,2,*} and Elazer R. Edelman, MD, PhD^{2,3}

¹Klinik für Innere Medizin III, Saarland University Hospital, Homburg/Saar, Germany

²Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA

³Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Hypertension is accompanied by significant adverse cardiovascular outcomes, and intensive blood pressure lowering (<120 mmHg) in patients at risk improves outcomes¹. However, although numerous highly effective pharmacological therapies are available to lower blood pressure, control rates remain unacceptably low. A substantial number of patients with hypertension are reluctant or incapable of adhering to lifestyle modification and/or poly pharmacotherapy regimens, especially as the former has a time-delimited impact on blood pressure and the latter requires a lifetime of adherence, which is challenging at best. Non-pharmacological control of blood pressure is appealing, and several interventional approaches have been developed and subsequently clinically investigated². One of these is catheter-based renal denervation. The method uses radiofrequency energy, alternatively ultrasound or chemical denervation, to disrupt renal nerves within the adventitia of the renal arteries, thereby reducing sympathetic afferent and efferent signalling to and from the kidneys³. The appeal here is that a single intervention might reduce blood pressure permanently or for a long time, removing the need for endless medication compliance.

There is widespread consensus that renal denervation can affect blood pressure in specific settings but there is similarly universal appreciation that the clinical evidence in support of renal denervation in resistant hypertension is mixed⁴. The interest in renal denervation has dropped significantly following the publication of the SYMPPLICITY HTN-3 trial⁵, in which the primary efficacy endpoint was missed. The randomised, controlled, DENERHTN trial⁶, however, documented superiority of renal denervation: it did meet its primary efficacy endpoint and showed superiority of renal denervation in combination with optimised pharmacotherapy when compared with pharmacotherapy alone. Research activities have picked up again recently with several randomised, sham-controlled studies currently including patients in Europe, the USA, Australia and Japan to answer a number of important questions in order to establish an evidence base for renal denervation as a treatment option in patients with uncontrolled hypertension. Inadequate patient selection, alterations in compliance with antihypertensive medication, insufficient technical performance of the

*Corresponding author: Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, 66421 Homburg/Saar, Germany. felix.mahfoud@uks.eu.

procedure, and several device features were acknowledged as potential confounders in previous studies⁷. This leaves us still to question whether renal denervation can be harnessed therapeutically. The urgency of treating hypertension and the lack of full resolution of the unanswered questions gnaw at the clinical community, and investigations and clinical trials continue.

Two interesting papers on renal denervation appear in this issue of *EuroIntervention* which, when taken in the context of ongoing clinical trials, add to our understanding of the field. van Zandvoort et al⁸ examined 27 patients with uncontrolled hypertension who underwent catheter-based renal denervation using magnetic resonance angiography (MRA). In this relatively small cohort of patients, there was no decrease in renal artery luminal dimensions at six- and twelve-month follow-up, nor was there any incidence of renal artery stenosis. These data are in line with other observations derived from the ENCOREd registry⁹, in which MRAs from 96 patients were analysed and new stenosis (25–49% lumen reduction) was seen in only two patients and progression of pre-existing lumen reduction in a single patient after a median time of 366 days post procedure. Similarly, the Global SYMPPLICITY Registry¹⁰ demonstrated a favourable safety profile in the first ~1,000 real-world patients from around the world.

Freyhardt et al¹¹ asked if a different approach to renal denervation could heighten efficacy without jeopardising safety. They investigated CT-guided periarterial injection of drugs to affect the innervation of renal arteries in place of radiofrequency or ultrasonic energy. Injection of vincristine significantly reduced noradrenaline kidney (NEPI) tissue concentration, a surrogate of sympathetic activity, and histological signs of nerve fibre degeneration. In contrast, hyperosmolar saline, paclitaxel, and guan-ethidine injections did not impose any relevant alterations. Of note, the reduction in NEPI (–53%) was less marked than has been observed in preclinical studies of catheter-based renal denervation (–70 to –95%)^{12,13}. Periarterial injection of vincristine may in principle represent an alternative, extravascular approach to achieve renal denervation but one might challenge the ease of use, the greater risk of collateral damage and potential complications associated with the CT-guided puncture, especially in obese patients, the higher radiation exposure compared with interventional approaches, and the overall complexity of the procedure. The observation that vincristine was superior to other drugs, however, is relevant and may prompt further investigations, also with the use of endovascular catheters that allow reliable peri-arterial injection of drugs¹⁴.

At the same time three major clinical trials will soon be reported.

1. The Symplcity Spyril clinical trial programme¹⁵ is studying the use of a multielectrode renal denervation system in patients with uncontrolled hypertension in the absence (SPYRAL HTN OFF-MED; n=100, NCT02439749) and presence (SPYRAL HTN ON-MED; n=100, NCT02439775) of antihypertensive drugs. These trials use the change in systolic blood pressure measured by 24-hour blood pressure from baseline to three months as an efficacy endpoint. The control groups receive sham treatment with renal angiography.

2. The RADIANCE-HTN (NCT02649426) trial compares ultrasonic renal denervation (Paradise[®] System; ReCor Medical, Palo Alto, CA, USA) to a sham procedure with the primary endpoint change in average daytime ambulatory systolic blood pressure from baseline to two months. Two cohorts are being investigated, namely patients without antihypertensive medication (SOLO, n=146) and patients treated with a fixed-dose triple antihypertensive drug regimen (TRIO, n=146). REQUIRE (NCT02918305, n=140) is designed to evaluate resistant hypertension patients on standard of care medication in Japan and Korea.
3. REDUCE HTN: REINFORCE (NCT02392351, n=100) studies the performance of the bipolar renal denervation system (Vessix[™]; Boston Scientific, Marlborough, MA, USA) over eight weeks compared to the sham effects of percutaneous renal angiography on mean reduction in daytime ambulatory systolic blood pressure in patients not treated with antihypertensive medication.

Research then continues and sometime soon the results of the ongoing studies will be available to enlighten our understanding of the role of renal denervation as an interventional treatment option for hypertensive patients. The studies will also provide relevant information for the clinical investigation of other emerging technologies such as arteriovenous anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation. Irrespective of the outcomes, the clinical and research community will be educated about the safety and feasibility of invasive sham procedures and their potential impact on biological parameters, such as blood pressure, in hypertensive patients. In the majority of the studies, adherence to antihypertensive medication will be measured meticulously using toxicological analyses, which will provide insights into potential compliance changes while participating in a clinical study investigating a new device-based treatment. Finally, we will understand whether a class effect of different devices can be assumed or whether distinct technologies are associated with distinct outcomes.

Renal denervation is probably facing its final chance to prove its value. 2017 will certainly be an exciting year for catheter-based renal denervation – stay tuned!

References

1. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015; 373:2103–16. [PubMed: 26551272]
2. Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. *Eur Heart J*. 2016 Jul 11. Epub ahead of print.
3. Böhm M, Linz D, Ukena C, Esler M, Mahfoud F. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? *Circ Res*. 2014; 115:400–9. [PubMed: 25035133]
4. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankstijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. *Eur Heart J*. 2015; 36:2219–27. [PubMed: 25990344]

5. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. *N Engl J Med*. 2014; 370:1393–401. [PubMed: 24678939]
6. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G. Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. *Lancet*. 2015; 385:1957–65. [PubMed: 25631070]
7. Mahfoud F, Lüscher TF. Renal denervation: simply trapped by complexity? *Eur Heart J*. 2015; 36:199–202. [PubMed: 25400163]
8. van Zandvoort L, van Kranenburg M, Antonios K, Van Mieghem N, Ouhlous M, van Geuns RJ, van Domburg R, Daemen J. Serial quantitative magnetic resonance angiography follow-up of renal artery dimensions following treatment by four different renal denervation systems. *EuroIntervention*. 2017; 12:2271–7.
9. Sanders MF, van Doormaal PJ, Beftink MM, Bots ML, Fadl Elmula FE, Habets J, Hammer F, Hoffmann P, Jacobs L, Mark PB, Persu A, Renkin J, Roditi G, Spiering W, Staessen JA, Taylor AH, Verloop WL, Vink EE, Vonken EJ, Voskuil M, Leiner T, Blankestijn PJ. European Network COordinating research on Renal Denervation (ENCOREd) Consortium. Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography. *Eur Radiol*. 2017 Mar 7. Epub ahead of print.
10. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirik A, Mancia G. GSR Investigators. First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. *Hypertension*. 2015; 65:766–74. [PubMed: 25691618]
11. Freyhardt P, Donners R, Riemert A, Schnorr J, Stolzenburg N, Rinnenthal JL, Bernhardt U, Hamm B, Günther RW, Streitparth F. Renal denervation by CT-guided periarterial injection of hyperosmolar saline, vincristine, paclitaxel and guanethidine in a pig model. *EuroIntervention*. 2017; 12:2262–70.
12. Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, Linz D, Davies J, Kandzari DE, Whitbourn R, Böhm M, Melder RJ. Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. *J Am Coll Cardiol*. 2015; 66:1766–75. [PubMed: 26483099]
13. Henegar JR, Zhang Y, Hata C, Narciso I, Hall ME, Hall JE. Catheter-Based Radiofrequency Renal Denervation: Location Effects on Renal Norepinephrine. *Am J Hypertens*. 2015; 28:909–14. [PubMed: 25576624]
14. Fischell TA, Fischell DR, Ghazarossian VE, Vega F, Ebner A. Next generation renal denervation: chemical perivascular renal denervation with alcohol using a novel drug infusion catheter. *Cardiovasc Revasc Med*. 2017; 16:221–7.
15. Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, Townsend R, Weber MA, Böhm M. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. *Am Heart J*. 2016; 171:82–91. [PubMed: 26699604]